| Literature DB >> 30248967 |
Yingting Cao1, Shiqi Zhen2, Anne W Taylor3, Sarah Appleton4, Evan Atlantis5,6, Zumin Shi7,8,9.
Abstract
(1) Background: In clinical trials, dietary magnesium use can improve insomnia symptoms. However, little is known about the association between dietary magnesium consumption and sleep disorder symptoms including daytime falling asleep, sleepiness and snoring at the population level. (2)Entities:
Keywords: Chinese adults; daytime falling asleep; dietary magnesium
Mesh:
Substances:
Year: 2018 PMID: 30248967 PMCID: PMC6212970 DOI: 10.3390/nu10101354
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Sample description from Jiangsu Nutrition Study.
Sex-specific characteristics of subjects by quartiles of magnesium consumption at baseline (2002) (n = 1487) 1.
| Quartiles of Magnesium Consumption (mg/day) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Men | Women | |||||||||
| Factors | Q1 ( | Q2 ( | Q3 ( | Q4 ( | Q1 ( | Q2 ( | Q3 ( | Q4 ( | ||
| Nutrients consumption | ||||||||||
| * Magnesium consumption (mg/day) | 219 (30.3) | 288 (16.4) | 350 (20.6) | 505 (122) | <0.001 | 186 (27.7) | 244 (13.1) | 301 (21.4) | 462 (132) | <0.001 |
| (124–259) | (259–315) | (315–392) | (392–1015) | (79–222) | (222–267) | (267–339) | (339–1157) | |||
| Carbohydrate (g/day) | 259 (62.1) | 317 (63.0) | 353 (86.3) | 427 (101) | <0.001 | 219 (56.5) | 277 (60.7) | 318 (65.9) | 392 (102) | <0.001 |
| Protein (g/d) | 61.3 (13.9) | 73.5 (14.9) | 84.3 (15.6) | 101.0 (23.5) | <0.001 | 51.5 (14.5) | 60.9 (13.5) | 69.1 (11.2) | 85.5 (23.7) | <0.001 |
| Fat (g/day) | 73.5 (26.7) | 84.7 (32.1) | 97.3 (36.4) | 104.6 (43.6) | <0.001 | 63.1 (23.3) | 70.6 (26.9) | 74.9 (28.1) | 88.6 (42.5) | <0.001 |
| Energy consumption (kcal) | 1968 (408) | 2389 (437) | 2700 (469) | 3195 (599) | <0.001 | 1639 (367) | 1976 (342) | 2211 (344) | 2707 (596) | <0.001 |
| Age (years) | 51.6 (14.1) | 49.6 (13.7) | 48.4 (13.0) | 48.8 (13.0) | 0.13 | 50.2 (14.8) | 48.3 (13.9) | 47.0 (12.1) | 46.9 (12.2) | 0.042 |
| BMI (kg/m2) | 23.8 (2.9) | 23.6 (3.6) | 23.1 (3.0) | 22.7 (3.1) | 0.013 | 23.5 (3.6) | 23.3 (3.9) | 23.9 (3.6) | 23.7 (3.3) | 0.29 |
| Income (%) | <0.001 | <0.001 | ||||||||
| Low | 20.4 | 15.5 | 18.9 | 37.9 | 14.9 | 21.7 | 20.3 | 46.6 | ||
| Medium | 32.7 | 39.8 | 32.1 | 27.3 | 38.0 | 38.2 | 38.6 | 24.8 | ||
| High | 46.9 | 44.7 | 49.1 | 34.8 | 47.1 | 40.1 | 41.1 | 28.6 | ||
| Education (%) | 0.19 | 0.004 | ||||||||
| Primary school | 44.2 | 35.6 | 33.7 | 45.1 | 55.0 | 52.6 | 61.7 | 71.6 | ||
| Junior middle school | 38.7 | 47.2 | 45.4 | 40.1 | 31.1 | 36.4 | 27.8 | 23.1 | ||
| Senior middle school | 11.7 | 14.7 | 17.8 | 13.0 | 12.9 | 10.0 | 10.5 | 4.8 | ||
| University | 5.5 | 2.5 | 3.1 | 1.9 | 1.0 | 1.0 | 0.0 | 0.5 | ||
| Smoking (%) | 58.9 | 61.3 | 55.8 | 64.8 | 0.40 | 2.9 | 3.8 | 1.0 | 4.3 | 0.19 |
| Alcohol consumption (%) | 0.002 | 0.17 | ||||||||
| Never | 62.0 | 50.3 | 43.8 | 40.4 | 95.7 | 97.1 | 94.7 | 91.9 | ||
| 1–2/week | 11.7 | 14.1 | 8.0 | 12.4 | 1.4 | 1.9 | 1.4 | 1.9 | ||
| 3–4/week | 7.4 | 7.4 | 8.6 | 8.7 | 1.0 | 1.0 | 1.9 | 1.4 | ||
| Daily | 19.0 | 28.2 | 39.5 | 38.5 | 1.9 | 0.0 | 1.9 | 4.8 | ||
| Sedentary activity (%) | 0.057 | 0.23 | ||||||||
| <1 h | 11.0 | 6.7 | 8.6 | 16.7 | 14.4 | 19.6 | 19.1 | 23.0 | ||
| 1–2 h | 23.9 | 30.1 | 24.5 | 32.1 | 27.8 | 30.1 | 33.5 | 34.0 | ||
| 2–3 h/day | 48.5 | 47.9 | 47.2 | 39.5 | 43.1 | 39.7 | 36.8 | 33.5 | ||
| ≥3 h/day | 16.6 | 15.3 | 19.6 | 11.7 | 14.8 | 10.5 | 10.5 | 9.6 | ||
| Manual occupation (%) | 34.0 | 50.3 | 52.8 | 63.0 | <0.001 | 28.2 | 50.7 | 54.1 | 66.0 | <0.001 |
| Region (%) | <0.001 | <0.001 | ||||||||
| Urban | 36.2 | 18.4 | 12.3 | 9.3 | 34.4 | 17.2 | 9.1 | 8.1 | ||
| Rural | 63.8 | 81.6 | 87.7 | 90.7 | 65.6 | 82.8 | 90.9 | 91.9 | ||
1 Participants presented were those with magnesium measurements at baseline (n = 2002) and participated in the follow-up (2007). Data are presented as mean (SD) for such values. * brackets after mean (SD) present magnesium consumption range in each quartile; BMI, body mass index, SD, standard deviation.
Sex-specific sleep outcomes of subjects by quartiles of magnesium consumption at baseline (2002) (n = 1487) 1.
| Quartiles of Magnesium Consumption (mg/day) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Men | Women | |||||||||
| Sleep variables | Q1 ( | Q2 ( | Q3 ( | Q4 ( | Q1 ( | Q2 ( | Q3 ( | Q4 ( | ||
| Sleep duration (%), (baseline) | ||||||||||
| 7–8 h/day | 64.2 | 77.0 | 68.3 | 64.2 | 0.19 | 71.2 | 69.9 | 66.7 | 67.0 | 0.11 |
| <7 h/day | 16.7 | 11.2 | 13.0 | 16.0 | 13.5 | 13.1 | 9.7 | 8.6 | ||
| ≥9 h/day | 19.1 | 11.8 | 18.6 | 19.8 | 15.4 | 17.0 | 23.7 | 24.4 | ||
| Sleep duration (%), (follow-up) | 0.27 | 0.039 | ||||||||
| 7–8 h/day | 74.2 | 65.4 | 70.6 | 73.5 | 65.1 | 63.5 | 65.6 | 72.2 | ||
| <7 h/day | 17.8 | 21.0 | 16.0 | 19.1 | 25.4 | 20.7 | 18.7 | 13.4 | ||
| 9–13 h/day | 8.0 | 13.6 | 13.5 | 7.4 | 9.6 | 15.9 | 15.8 | 14.4 | ||
| Falling sleep (%) | 4.9 | 8.6 | 5.0 | 3.7 | 0.24 | 8.7 | 4.4 | 5.3 | 1.9 | 0.018 |
| Daytime sleepiness (%) | 12.3 | 14.7 | 14.3 | 13.6 | 0.92 | 15.9 | 13.0 | 9.6 | 12.9 | 0.29 |
| Snore (%) | 47.5 | 51.5 | 49.7 | 46.3 | 0.79 | 26.8 | 26.6 | 26.3 | 22.5 | 0.71 |
1 Participants presented were those with magnesium measurements at baseline (n = 2002) and participated in the follow-up (2007). Data are presented as mean (SD) for such values.
The odds ratios (OR (95% CI)) of self-reported sleep disorder symptoms at follow-up (2007) according to magnesium consumption (mg) quartiles at baseline (2002) (n = 1487) 1.
| Magnesium Consumption (mg/day) | |||||
|---|---|---|---|---|---|
| Sleep disorder symptoms | Men | ||||
| Falling asleep |
| Q1 ( | Q2 ( | Q3 ( | Q4 ( |
| Model 1 | 645 | 1.00 | 1.89 (0.73, 4.86) | 1.07 (0.35, 3.34) | 0.80 (0.20, 3.22) |
| Model 2 | 635 | 1.00 | 2.32 (0.86, 6.27) | 1.32 (0.40, 4.34) | 1.38 (0.33, 5.73) |
| Model 3 | 607 | 1.00 | 2.53 (0.93, 6.90) | 1.32 (0.40, 4.34) | 1.44 (0.34, 6.04) |
| Model 4 | 606 | 1.00 | 2.51 (0.91, 6.91) | 1.20 (0.36, 4.06) | 1.36 (0.31, 5.98) |
| Women | |||||
| Q1 ( | Q2 ( | Q3 ( | Q4 ( | ||
| Model 1 | 831 | 1.00 | 0.40 (0.17, 0.94) * | 0.43 (0.18, 1.05) | 0.10 (0.02, 0.43) ** |
| Model 2 | 795 | 1.00 | 0.35 (0.14, 0.87) * | 0.41 (0.16, 1.04) | 0.10 (0.02, 0.47) ** |
| Model 3 | 795 | 1.00 | 0.32 (0.13, 0.81) * | 0.37 (0.14, 0.97) * | 0.09 (0.02, 0.43) ** |
| Model 4 | 792 | 1.00 | 0.34 (0.14, 0.87) * | 0.42 (0.16, 1.09) | 0.11 (0.02, 0.57) ** |
| Men | |||||
| Daytime sleepiness |
| Q1 ( | Q2 ( | Q3 ( | Q4 ( |
| Model 1 | 649 | 1.00 | 1.30 (0.70, 2.42) | 1.34 (0.68, 2.63) | 1.36 (0.61, 3.03) |
| Model 2 | 639 | 1.00 | 1.33 (0.71, 2.49) | 1.38 (0.69, 2.78) | 1.54 (0.68, 3.49) |
| Model 3 | 638 | 1.00 | 1.33 (0.70, 2.50) | 1.41 (0.70, 2.83) | 1.64 (0.72, 3.70) |
| Model 4 | 637 | 1.00 | 1.32 (0.69, 2.50) | 1.39 (0.68, 2.83) | 1.62 (0.69, 3.80) |
| Women | |||||
| Q1 ( | Q2 ( | Q3 ( | Q4 ( | ||
| Model 1 | 834 | 1.00 | 0.84 (0.50, 1.43) | 0.64 (0.34, 1.17) | 0.87 (0.43, 1.73) |
| Model 2 | 825 | 1.00 | 0.83 (0.49, 1.42) | 0.63 (0.34, 1.17) | 0.98 (0.47, 2.02) |
| Model 3 | 825 | 1.00 | 0.83 (0.48, 1.42) | 0.62 (0.33, 1.16) | 0.99 (0.48, 2.05) |
| Model 4 | 821 | 1.00 | 0.84 (0.49, 1.44) | 0.61 (0.33, 1.14) | 1.00 (0.47, 2.08) |
| Men | |||||
| Snoring |
| Q1 ( | Q2 ( | Q3 ( | Q4 ( |
| Model 1 | 645 | 1.00 | 1.12 (0.81, 1.55) | 1.11 (0.78, 1.58) | 1.06 (0.69, 1.61) |
| Model 2 | 635 | 1.00 | 1.06 (0.76, 1.47) | 1.07 (0.74, 1.55) | 1.11 (0.72, 1.71) |
| Model 3 | 607 | 1.00 | 1.05 (0.75, 1.47) | 1.10 (0.76, 1.59) | 1.15 (0.74, 1.80) |
| Model 4 | 607 | 1.00 | 1.04 (0.75, 1.46) | 1.08 (0.74, 1.56) | 1.10 (0.70, 1.75) |
| Women | |||||
| Q1 ( | Q2 ( | Q3 ( | Q4 ( | ||
| Model 1 | 834 | 1.00 | 0.95 (0.65, 1.40) | 0.93 (0.61, 1.40) | 0.71 (0.42, 1.20) |
| Model 2 | 825 | 1.00 | 0.97 (0.65, 1.43) | 0.94 (0.62, 1.44) | 0.80 (0.46, 1.37) |
| Model 3 | 825 | 1.00 | 1.00 (0.68, 1.49) | 0.91 (0.59, 1.39) | 0.85 (0.50, 1.46) |
| Model 4 | 821 | 1.00 | 1.01 (0.68, 1.49) | 0.91 (0.60, 1.39) | 0.89 (0.52, 1.55) |
1 Participants included in the model had magnesium consumption at baseline (2002) and participated at follow-up (2007) (n = 1487, men (n = 651)). Q1–Q4 stands for quartiles of isoflavone consumption for each sex. Model 1 adjusted for age and energy consumption; Model 2 further adjusted for income, education, rural region, smoking, alcohol consumption and sedentary activity; Model 3 further adjusted for BMI, hypertension, and diabetes. Model 4 further adjusted for dietary patterns; Four dietary patterns (previously published) are: Factor 1 (‘macho’) included various kinds of animal foods and alcohol; Factor 2 (the ‘traditional’ pattern) loaded heavily on rice, fresh vegetables and inversely on wheat flour; Factor 3 (‘sweet tooth’) contained cake, milk, yoghurt and drinks; and, Factor 4 (‘vegetable rich’ pattern) was characterized whole grains, fruits, root vegetables, fresh and pickled vegetables, milk, eggs and fish. The four factors explained 28.5% of the variance in intake (published earlier [16]). * p < 0.05, ** p < 0.01.